Results 171 to 180 of about 53,092 (237)

Rezdiffra™ (resmetirom): a THR-β agonist for non-alcoholic steatohepatitis. [PDF]

Trends Pharmacol Sci
Brisnovali NF, Haney C, Goedeke L.
europepmc   +1 more source

Post‐TIPS Dynamics of von Willebrand Factor for Risk Stratification After TIPS Placement

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background & Aims Transjugular intrahepatic portosystemic shunt (TIPS) placement is used to treat complications of portal hypertension. This study aimed to evaluate the prognostic value of von Willebrand factor antigen (VWF) dynamics following TIPS placement.
Marlene Hintersteininger, Simon Johannes Gairing, Katrin Kirsch, Theresa Müllner‐Bucsics, Susanna Riegler, Lukas Reider, Mathias Jachs, Lorenz Balcar, Eva M. Schleicher, Jasmin Söhngen, Lukas Müller, Michael B. Pitton, Julia Weinmann‐Menke, Christian M. Lange, Peter R. Galle, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Christian Labenz, Lukas Hartl   +19 more
wiley   +1 more source

Ethanol extract of Polygonatum cyrtonema Hua mitigates non-alcoholic steatohepatitis in mice. [PDF]

Front Pharmacol
Chen D, Shen Y, Huang F, Huang B, Xu S, Li L, Liu J, Li Z, Li X.   +8 more
europepmc   +1 more source

Integrative Multi‐Omics Analysis Elucidates the Progressive Disease Landscape and Reveals Dynamic Protein Biomarkers for MASLD Surveillance

The FASEB Journal, Volume 40, Issue 12, 30 June 2026.
Integrated transcriptomic, single‐cell, pseudotime, cell–cell communication, human tissue, and in vivo analyses define a dynamic four‐gene axis across the MASLD continuum. Progressive CYP2C19 downregulation and AKR1B10, COL1A2, and SPP1 upregulation link metabolic dysfunction to disease progression, while AKR1B10 knockdown or CYP2C19 overexpression ...
Kejun Liu, Bozhi Zhang, Yezhen Tang, Zhenyao Tan, Yang Bu, Yongxue Lv   +5 more
wiley   +1 more source

A New Hope for the Patients of Non-Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use. [PDF]

Health Sci Rep
Hasan AH, Abid MA, Abid MH, Suhail L, Nazir A.   +4 more
europepmc   +1 more source

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma

International Journal of Cancer, Volume 158, Issue 12, Page 3252-3267, 15 June 2026.
What's new? Oncolytic viruses are a promising immunotherapeutic approach against many malignancies. However, it is unclear whether repeated doses have improved therapeutic value or may trigger greater side effects, especially in patients with hepatocellular carcinoma whose liver is chronically damaged.
Karen J. Scott, Emma J. West, Rebecca J. Brownlie, Fay Ismail, Christy Ralph, Thomas Heineman, Matt Coffey, Alan A. Melcher, Alison Taylor, Salvatore Papa, Adel Samson   +10 more
wiley   +1 more source

Potential diagnostic marker gene set for non-alcoholic steatohepatitis associated hepatocellular carcinoma with lymphocyte infiltration. [PDF]

Transl Cancer Res
Wang X, Gao M, Zhang Z, Ao X, Luo A, Wen Z, Pan X, Sun M, Wang T, Jia Z.   +9 more
europepmc   +1 more source

Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy. [PDF]

Front Pharmacol
Lin Z, Yang M, Yu X, Tan G, Zhong J.
europepmc   +1 more source

A comparison of trends in the incidence of non-alcoholic steatohepatitis-related liver cancer in the BRICS countries from 1990 to 2021, alongside projections for the next 15 years. [PDF]

Front Oncol
Chen C, Huang S, Wu H, Hu W, Li C, Du D, Fang T.   +6 more
europepmc   +1 more source

Machine learning-based models for advanced fibrosis in non-alcoholic steatohepatitis patients: A cohort study. [PDF]

World J Gastroenterol
Xiong FX, Sun L, Zhang XJ, Chen JL, Zhou Y, Ji XM, Meng PP, Wu T, Wang XB, Hou YX.   +9 more
europepmc   +1 more source